Skip to content
Biodatica
Start free

The Lymphoma Academic Research Organisation

Bruges

OncologyCAR-TPhase III
Compare Sign in to watch

What changed

Phase II trial registered: Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma

1w agoTrial registeredJul 10, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

626 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Dec 1, 2025

    Large B-cell Lymphoma · RECRUITING · sponsor: The Lymphoma Academic Research Organisation · Glofitamab in Real Life

    ClinicalTrials.gov · NCT06994169 (opens the source filing in a new tab)

  2. Trial

    PHASE3 registered

    Aug 27, 2025

    Sickle Cell Disease, Acute Chest Syndrome · RECRUITING · sponsor: Assistance Publique - Hôpitaux de Paris · Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease

    ClinicalTrials.gov · NCT06818266 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Feb 21, 2025

    Lymphoma, Mantle-Cell · RECRUITING · sponsor: The Lymphoma Academic Research Organisation · Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma

    ClinicalTrials.gov · NCT06558604 (opens the source filing in a new tab)

  4. Trial

    PHASE2 registered

    Nov 30, 2023

    Mantle Cell Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: University College, London · Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma

    ClinicalTrials.gov · NCT05004064 (opens the source filing in a new tab)

  5. Trial

    PHASE2 registered

    Jan 24, 2022

    Mantle Cell Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: The Lymphoma Academic Research Organisation · Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

    ClinicalTrials.gov · NCT04802590 (opens the source filing in a new tab)

  6. Trial

    PHASE2/PHASE3 registered

    Jan 12, 2022

    Sickle Cell Disease · COMPLETED · sponsor: Assistance Publique - Hôpitaux de Paris · Interest of Famotidine in Children With Sickle Cell Disease

    ClinicalTrials.gov · NCT05084521 (opens the source filing in a new tab)

  7. Trial

    Study registered

    Dec 19, 2019

    Hematopathology Eligible or CAR-t Cell Treatment · RECRUITING · sponsor: The Lymphoma Academic Research Organisation · French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)

    ClinicalTrials.gov · NCT04328298 (opens the source filing in a new tab)

  8. Trial

    PHASE2 registered

    Nov 29, 2016

    Mantle Cell Lymphoma · COMPLETED · sponsor: The Lymphoma Academic Research Organisation · Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance

    ClinicalTrials.gov · NCT02896582 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources